Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15973709 | 0.88 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL13668088 | 0.83 | KMT2A (0.57) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL13670497 | 0.83 | KMT2A (0.57) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL11270312 | 0.83 | GAA (0.74) | ALDH1A1L3MBTL1KMT2AMEN1POLB | |
| SCHEMBL11290809 | 0.83 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL11292746 | 0.83 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL29721615 | 0.82 | HDAC1 (0.58) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL11288323 | 0.82 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL11292942 | 0.81 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A | |
| SCHEMBL11289748 | 0.81 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1LMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | ALDH1A1 1500/4885L3MBTL1 1550/4885LMNA 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.